Jhalak Dholakia, MD, Highlights Promise of Neoadjuvant Carboplatin/Mirvetuximab Soravtansine in Advanced Ovarian Cancer


Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Jhalak Dholakia, MD, a fellow at the University of Alabama, discussed the promise of carboplatin and mirvetuximab soravtansine as a neoadjuvant treatment for folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.

In particular, Dholakia explained that if findings from the ongoing phase 2 study (NCT04606914) assessing the combination prove to be positive, it will be exciting to have a neoadjuvant targeted therapy available for this patient population.


It’s really exciting that we could use targeted therapy in the neoadjuvant setting [for patients with advanced-stage disease]. This is a new, exciting place that we’re going in gynecologic oncology and in ovarian cancer. I could very conceivably see this being used for other targeted therapies or other agents in order to really do the most we can up front with the most information we have for our patients.


Dholakia J. Single-arm phase II trial of carboplatin and mirvetuximab soravtansine as neoadjuvant chemotherapy (NACT) for advanced-stage ovarian, fallopian tube or primary peritoneal cancer (EOC) who are folate receptor a positive (NCT04606914). Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content